Log in

NASDAQ:ORGOOrganogenesis Stock Price, Forecast & News

$4.02
+0.16 (+4.15 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.85
Now: $4.02
$4.15
50-Day Range
$3.32
MA: $3.77
$3.99
52-Week Range
$2.47
Now: $4.02
$8.34
Volume337,003 shs
Average Volume147,293 shs
Market Capitalization$426.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORGO
CUSIPN/A
CIKN/A
Phone781-575-0775

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$260.98 million
Book Value$0.59 per share

Profitability

Net Income$-40,450,000.00

Miscellaneous

Employees700
Market Cap$426.56 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableNot Optionable
$4.02
+0.16 (+4.15 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

How has Organogenesis' stock been impacted by COVID-19 (Coronavirus)?

Organogenesis' stock was trading at $2.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ORGO stock has increased by 34.9% and is now trading at $4.02.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Organogenesis?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Organogenesis
.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Organogenesis
.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc (NASDAQ:ORGO) issued its earnings results on Monday, May, 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.03. The firm earned $61.73 million during the quarter, compared to analyst estimates of $61.30 million. Organogenesis had a negative net margin of 15.48% and a negative return on equity of 124.66%.
View Organogenesis' earnings history
.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $68-68.6 million, compared to the consensus revenue estimate of $48.25 million.

What price target have analysts set for ORGO?

4 brokers have issued 1 year target prices for Organogenesis' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Organogenesis' stock price to reach $7.75 in the next year. This suggests a possible upside of 92.8% from the stock's current price.
View analysts' price targets for Organogenesis
.

Has Organogenesis been receiving favorable news coverage?

Press coverage about ORGO stock has been trending negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organogenesis earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Organogenesis
.

Are investors shorting Organogenesis?

Organogenesis saw a decrease in short interest in July. As of July 31st, there was short interest totaling 384,500 shares, a decrease of 19.0% from the July 15th total of 474,400 shares. Based on an average daily trading volume, of 211,500 shares, the short-interest ratio is currently 1.8 days. Currently, 3.3% of the shares of the company are short sold.
View Organogenesis' Short Interest
.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Gilead Sciences (GILD), Energy Transfer LP Unit (ET), Ford Motor (F), Carnival (CCL), General Motors (GM), Opko Health (OPK), Ovid Therapeutics (OVID), Occidental Petroleum (OXY), vTv Therapeutics (VTVT) and AMC Entertainment (AMC).

Who are Organogenesis' key executives?

Organogenesis' management team includes the following people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)
  • Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 57)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)
  • Angelyn Lowe, Director of Corp. Communications

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $4.02.

How big of a company is Organogenesis?

Organogenesis has a market capitalization of $426.56 million and generates $260.98 million in revenue each year. The company earns $-40,450,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Organogenesis employs 700 workers across the globe.

What is Organogenesis' official website?

The official website for Organogenesis is organogenesis.com.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.